Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort
| Autor: | Claudio Estepo, Ana Palazzo, Virginia Reggiardo, Margarita Anders, Federico Piñero, Raúl Adrover, Alejandro Soza, Maria Isabel Schinoni, Alexandre de Araujo, Andres Bruno, Marcela Sixto, Silvia Borzi, Mirta Peralta, Ezequiel Ridruejo, Daniela Perez, Luisa Santos, Adriana Varón, Daniel Cocozzella, María Grazia Videla Zuain, Valeria Descalzi, Manuel Mendizabal, Alina Zerega, Nelia Hernández, Nora Fernández, Beatriz Ameigeiras, Marcelo Silva, Federico Tanno, Fernando Herz Wolff, Cristina Alonso, Sebastián Figueroa, Cecilia Vistarini, Hugo Cheinquer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Cirrhosis business.industry Ribavirin medicine.medical_treatment Odds ratio Hepatitis C Liver transplantation medicine.disease Virology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Infectious Diseases chemistry Internal medicine Cohort medicine 030211 gastroenterology & hepatology 030212 general & internal medicine Liver function business Cohort study |
| Zdroj: | Journal of medical virologyREFERENCES. |
| ISSN: | 1096-9071 0377-5798 |
| Popis: | INTRODUCTION Although the effectiveness of direct-acting antivirals (DAAs) for the treatment of chronic hepatitis C virus (HCV) has been reported in real-world settings, predictive factors of treatment failure are lacking. Therefore, we sought to explore the baseline predictors of treatment response to DAAs. METHODS This was a prospective multicenter cohort study from the Latin American Liver Research Educational and Awareness Network (LALREAN) including patients who received DAA treatment from May 2016 to April 2019. A multivariate logistic regression model was conducted to identify variables associated with unachieved sustained virological response (SVR), defined as treatment failure (odds ratios [OR] and 95% confidence intervals [CIs]). RESULTS From 2167 patients (55.2% with cirrhosis) who initiated DAA therapy, 89.4% completed a full-course treatment (n = 1938). Median treatment duration was 12 weeks, and 50% received ribavirin. Definitive suspension due to intolerance or other causes was observed in only 1.0% cases (n = 20). Overall non-SVR12 was 4.5% (95% CI, 3.5-5.7). There were no significant differences in treatment failure according to HCV genotypes and the degree of fibrosis. Independently associated variables with DAA failure were liver function impairment according to the Child-Pugh score B OR, 2.09 (P = .06), Child-Pugh C OR, 11.7 (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text